Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells

Breast tumor interleukin-6 (IL-6) levels increase with tumor grade, and elevated serum IL-6 correlates with poor breast cancer patient survival. Epithelial–mesenchymal transition (EMT) phenotypes such as impaired E-cadherin expression or aberrant Vimentin induction are associated with enhanced metastasis and unfavorable clinical outcome in breast cancer. Despite this fact, few tumor microenvironment-derived extracellular signaling factors capable of provoking such a phenotypic transition have been identified. In this study, we showed that IL-6 promoted E-cadherin repression among a panel of estrogen receptor-α-positive human breast cancer cells. Furthermore, ectopic stable IL-6 expressing MCF-7 breast adenocarcinoma cells (MCF-7IL−6) exhibited an EMT phenotype characterized by impaired E-cadherin expression and induction of Vimentin, N-cadherin, Snail and Twist. MCF-7IL−6 cells formed xenograft tumors that displayed loss of E-cadherin, robust Vimentin induction, increased proliferative indices, advanced tumor grade and undifferentiated histology. Finally, we showed aberrant IL-6 production and STAT3 activation in MCF-7 cells that constitutively express Twist, a metastatic regulator and direct transcriptional repressor of E-cadherin. To our knowledge, this is the first study that shows IL-6 as an inducer of an EMT phenotype in breast cancer cells and implicates its potential to promote breast cancer metastasis.

[1]  M. Takeichi,et al.  Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.

[2]  D. Laune,et al.  Oestrogen receptor negative breast cancers exhibit high cytokine content , 2007, Breast Cancer Research.

[3]  Cynthia A. Reinhart-King,et al.  Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.

[4]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[5]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[6]  Wei Zhang,et al.  Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. , 2005, The American journal of pathology.

[7]  C. Heldin,et al.  Transforming growth factor-β employs HMGA2 to elicit epithelial–mesenchymal transition , 2006, The Journal of cell biology.

[8]  M. Wojtukiewicz,et al.  Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. , 2003, Roczniki Akademii Medycznej w Bialymstoku.

[9]  S. Fernandez,et al.  Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. , 2007, Cancer letters.

[10]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[11]  A. Axel,et al.  Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer , 2007 .

[12]  R. Elliott,et al.  Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. , 2000, Cytokine.

[13]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[14]  H. Beug,et al.  ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. , 2006, Cancer cell.

[15]  D. Newgreen,et al.  Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors , 2007, Breast Cancer Research.

[16]  Guo‐Jun Zhang,et al.  Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. , 1999, Anticancer research.

[17]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[18]  T. Rosol,et al.  Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. , 2008, Cancer research.

[19]  S. Hellman,et al.  Individual characterisation of the metastatic capacity of human breast carcinoma. , 2000, European journal of cancer.

[20]  D. Weaver,et al.  Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. , 2001, Cancer research.

[21]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[22]  W. Reichelt,et al.  Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols , 2004, Molecular Cancer.

[23]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[24]  T. Kishimoto.  Interleukin-6: discovery of a pleiotropic cytokine , 2006, Arthritis research & therapy.

[25]  K. B. Pedersen,et al.  Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies , 2002, British Journal of Cancer.

[26]  J. Karras,et al.  Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. , 2004, Molecular cancer therapeutics.

[27]  A. Purohit,et al.  The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. , 1999, Endocrine-related cancer.

[28]  J. Blay,et al.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients , 2003, British Journal of Cancer.

[29]  E. van Marck,et al.  Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer , 2003, International journal of cancer.

[30]  A. Nicolini,et al.  Cytokines in breast cancer. , 2006, Cytokine & growth factor reviews.

[31]  D. Coppola,et al.  Twist Is Transcriptionally Induced by Activation of STAT3 and Mediates STAT3 Oncogenic Function* , 2008, Journal of Biological Chemistry.

[32]  P. V. van Diest,et al.  Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. , 2005, Cancer research.

[33]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[34]  P. Heinrich,et al.  Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. , 1993, The Journal of biological chemistry.

[35]  A. Axel,et al.  Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[37]  J. Turkson,et al.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.

[38]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[39]  S. Eschrich,et al.  Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[40]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.